Videos


Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.  

Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management

Articles

Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.

Expert Expects T-DM1 to Transform Treatment in HER2+ Breast Cancer

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. Geyer on Impact of Targeted Agents in HER2+ Breast Cancer

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer

Studies conducted at VCU Massey Cancer Center
in Richmond, Virginia, over the past 7 years
have developed the therapeutic combination of
pemetrexed and sorafenib (Nexavar) from
the bench to the bedside, and now into phase II clinical
trial evaluation.

VCU Massey Cancer Center

Latest from VCU Massey Cancer Center

New content coming soon, please check back later.